undisclosed UK drug development

Dark Blue Therapeutics is an Oxford-based biotechnology company specializing in the discovery and development of precision oncology medicines. The company focuses on exploiting novel cancer vulnerabilities through targeted protein degradation and small molecule inhibition, particularly targeting epigenetic and transcriptional regulators. Its lead program, DBT 3757, is a first-in-class small molecule degrader of MLLT1/3 designed to treat acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In January 2026, the company was acquired by Amgen for up to $840 million to bolster Amgen's oncology pipeline and expertise in protein degradation.